Patents by Inventor Joseph McCrary McCune

Joseph McCrary McCune has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CD47 targeted therapies for the treatment of infectious disease
    Patent number: 11780931
    Abstract: Methods are provided for treating a subject with for an intracellular pathogen infection, by administering an agent that reduces the binding of CD47 on a infected cell to SIRP? on a host phagocytic cell, in an effective dose for increasing the phagocytosis of infected cells.
    Type: Grant
    Filed: December 14, 2021
    Date of Patent: October 10, 2023
    Assignees: The Board of Trustees of the Leland Stanford Junior University, The United States of America, as represented by the Secretary, Department of Health and Human Services, The Regents of the University of California
    Inventors: Kipp Andrew Weiskopf, Kim J. Hasenkrug, Cheryl A. Stoddart, Joseph McCrary McCune, Irving L. Weissman
  • CD47 TARGETED THERAPIES FOR THE TREATMENT OF INFECTIOUS DISEASE
    Publication number: 20220098322
    Abstract: Methods are provided for treating a subject with for an intracellular pathogen infection, by administering an agent that reduces the binding of CD47 on a infected cell to SIRP? on a host phagocytic cell, in an effective dose for increasing the phagocytosis of infected cells.
    Type: Application
    Filed: December 14, 2021
    Publication date: March 31, 2022
    Inventors: Kipp Andrew Weiskopf, Kim J. Hasenkrug, Cheryl A. Stoddart, Joseph McCrary McCune, Irving L. Weissman
  • CD47 targeted therapies for the treatment of infectious disease
    Patent number: 11230607
    Abstract: Methods are provided for treating a subject with for an intracellular pathogen infection, by administering an agent that reduces the binding of CD47 on a infected cell to SIRP? on a host phagocytic cell, in an effective dose for increasing the phagocytosis of infected cells.
    Type: Grant
    Filed: June 15, 2020
    Date of Patent: January 25, 2022
    Assignees: The Board of Trustees of the Leland Stanford Junior University, The United States of America as represented by the Secretary, Department of Health and Human Services, The Regents of the University of California
    Inventors: Kipp Andrew Weiskopf, Kim J. Hasenkrug, Cheryl A. Stoddart, Joseph McCrary McCune, Irving L. Weissman
  • CD47 TARGETED THERAPIES FOR THE TREATMENT OF INFECTIOUS DISEASE
    Publication number: 20200354469
    Abstract: Methods are provided for treating a subject with for an intracellular pathogen infection, by administering an agent that reduces the binding of CD47 on a infected cell to SIRP? on a host phagocytic cell, in an effective dose for increasing the phagocytosis of infected cells.
    Type: Application
    Filed: June 15, 2020
    Publication date: November 12, 2020
    Inventors: Kipp Andrew Weiskopf, Kim J. Hasenkrug, Cheryl A. Stoddart, Joseph McCrary McCune, Irving L. Weissman
  • CD47 targeted therapies for the treatment of infectious disease
    Patent number: 10723803
    Abstract: Methods are provided for treating a subject with for an intracellular pathogen infection, by administering an agent that reduces the binding of CD47 on a infected cell to SIRP? on a host phagocytic cell, in an effective dose for increasing the phagocytosis of infected cells.
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: July 28, 2020
    Assignees: The Board of Trustees of the Leland Stanford Junior University, The United States of America, as represented by the Secretary, Department of Health and Human Services, The Regents of the University of California
    Inventors: Kipp Andrew Weiskopf, Kim J. Hasenkrug, Cheryl A. Stoddart, Joseph McCrary McCune, Irving L. Weissman
  • CD47 TARGETED THERAPIES FOR THE TREATMENT OF INFECTIOUS DISEASE
    Publication number: 20190092873
    Abstract: Methods are provided for treating a subject with for an intracellular pathogen infection, by administering an agent that reduces the binding of CD47 on a infected cell to SIRP? on a host phagocytic cell, in an effective dose for increasing the phagocytosis of infected cells.
    Type: Application
    Filed: December 10, 2018
    Publication date: March 28, 2019
    Inventors: Kipp Andrew Weiskopf, Kim J. Hasenkrug, Cheryl A. Stoddart, Joseph McCrary McCune, Irving L. Weissman
  • CD47 targeted therapies for the treatment of infectious disease
    Patent number: 10184004
    Abstract: Methods are provided for treating a subject with for an intracellular pathogen infection, by administering an agent that reduces the binding of CD47 on a infected cell to SIRP? on a host phagocytic cell, in an effective dose for increasing the phagocytosis of infected cells.
    Type: Grant
    Filed: August 14, 2017
    Date of Patent: January 22, 2019
    Assignees: The Board of Trustees of the Leland Stanford Junior University, The Regents of the University of California, The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Kipp Andrew Weiskopf, Kim J. Hasenkrug, Cheryl A. Stoddart, Joseph McCrary McCune, Irving L. Weissman
  • CD47 TARGETED THERAPIES FOR THE TREATMENT OF INFECTIOUS DISEASE
    Publication number: 20170362332
    Abstract: Methods are provided for treating a subject with for an intracellular pathogen infection, by administering an agent that reduces the binding of CD47 on a infected cell to SIRP? on a host phagocytic cell, in an effective dose for increasing the phagocytosis of infected cells.
    Type: Application
    Filed: August 14, 2017
    Publication date: December 21, 2017
    Inventors: Kipp Andrew Weiskopf, Kim J. Hasenkrug, Cheryl A. Stoddart, Joseph McCrary McCune, Irving L. Weissman
  • Extended human hematopoiesis in a heterologous host
    Patent number: 6093872
    Abstract: A human hematopoietic system is provided in an immunocompromised mammalian host, where the hematopoietic system is functional for extended periods of time. Particularly, human fetal liver tissue and human fetal thymus is introduced into an appropriate site of a young immunocompromised mouse at a site supplied with a vascular system, whereby the fetal tissue results in novel formation of functional human bone marrow tissue.
    Type: Grant
    Filed: February 13, 1992
    Date of Patent: July 25, 2000
    Assignee: Systemix, Inc.
    Inventors: Hideto Kaneshima, Reiko Namikawa, Joseph McCrary McCune